Magnolia Capital Advisors LLC acquired a new position in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 10,910 shares of the medical device company’s stock, valued at approximately $735,000.
Other hedge funds have also made changes to their positions in the company. Geode Capital Management LLC raised its position in shares of DexCom by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 11,006,183 shares of the medical device company’s stock worth $727,842,000 after acquiring an additional 42,411 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in DexCom by 6.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,999,057 shares of the medical device company’s stock valued at $530,897,000 after purchasing an additional 516,526 shares in the last quarter. Norges Bank acquired a new position in DexCom in the fourth quarter valued at approximately $483,356,000. Invesco Ltd. increased its stake in DexCom by 14.8% in the fourth quarter. Invesco Ltd. now owns 5,315,367 shares of the medical device company’s stock valued at $352,781,000 after purchasing an additional 686,228 shares during the last quarter. Finally, CIBC Private Wealth Group LLC increased its stake in DexCom by 7.6% in the fourth quarter. CIBC Private Wealth Group LLC now owns 3,128,114 shares of the medical device company’s stock valued at $207,613,000 after purchasing an additional 220,313 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.
Insider Activity
In other news, EVP Jon Coleman sold 4,912 shares of the firm’s stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $73.00, for a total value of $358,576.00. Following the completion of the sale, the executive vice president owned 100,361 shares in the company, valued at approximately $7,326,353. This trade represents a 4.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $75.55, for a total transaction of $128,435.00. Following the completion of the sale, the executive vice president directly owned 106,353 shares in the company, valued at approximately $8,034,969.15. The trade was a 1.57% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 73,035 shares of company stock valued at $5,446,673. 0.28% of the stock is owned by corporate insiders.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Report on DexCom
DexCom Stock Performance
Shares of DXCM stock opened at $88.96 on Thursday. The stock’s 50-day moving average price is $78.50 and its 200 day moving average price is $71.33. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $33.57 billion, a PE ratio of 35.16, a price-to-earnings-growth ratio of 1.50 and a beta of 1.41. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $92.59.
DexCom (NASDAQ:DXCM – Get Free Report) last announced its earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.61 by $0.09. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The company had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.29 billion. During the same period last year, the business posted $0.48 EPS. The company’s revenue was up 13.1% on a year-over-year basis. As a group, equities research analysts forecast that DexCom, Inc. will post 2.64 EPS for the current year.
DexCom Company Profile
DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.
Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.
Featured Articles
- Five stocks we like better than DexCom
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM – Free Report).
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.
